2.66
Gain Therapeutics Inc 주식(GANX)의 최신 뉴스
How Gain Therapeutics Inc. stock compares to industry benchmarksWeekly Profit Report & Expert Approved Trade Ideas - newser.com
Gain Therapeutics presents data on GT-02287 - TipRanks
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - The Manila Times
Gain Therapeutics (Nasdaq: GANX) Reports GT-02287 Mitochondrial, Neuronal Data - Stock Titan
Will Gain Therapeutics Inc. stock deliver strong dividend growthInsider Buying & Real-Time Volume Analysis Alerts - newser.com
Gain Therapeutics Inc. stock outlook for YEARJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
Is Gain Therapeutics Inc. stock ready for a breakoutWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Can machine learning forecast Gain Therapeutics Inc. recovery2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know - sharewise.com
How does Gain Therapeutics Inc (GANX) change from a tortoise to a hare? - Setenews
Is Gain Therapeutics Inc. stock undervalued vs historical averagesQuarterly Market Summary & Consistent Growth Stock Picks - newser.com
Equities Analysts Set Expectations for GANX FY2025 Earnings - Defense World
Will Gain Therapeutics Inc. stock go up soon2025 Price Targets & AI Enhanced Trading Signals - newser.com
Can Gain Therapeutics Inc. stock deliver sustainable ROEWeekly Trade Summary & AI Enhanced Trade Execution Alerts - newser.com
Why Gain Therapeutics Inc. stock remains on buy listsJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Is Gain Therapeutics Inc. stock a buy before product launchesMarket Trend Review & Safe Capital Preservation Plans - newser.com
Building trade automation scripts for Gain Therapeutics Inc.Weekly Trading Summary & Verified Momentum Watchlists - newser.com
Gain Therapeutics Reports Continued Progress Amid Financial Challenges - The Globe and Mail
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Day 6 of Gains Streak for Gain Therapeutics Stock with 78% Return (vs. 37% YTD) [11/12/2025] - Trefis
[8-K] Gain Therapeutics, Inc. Reports Material Event | GANX SEC FilingForm 8-K - Stock Titan
[10-Q] Gain Therapeutics, Inc. Quarterly Earnings Report | GANX SEC FilingForm 10-Q - Stock Titan
Gain Therapeutics reports Q3 EPS (15c), consensus (15c) - TipRanks
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics (NASDAQ: GANX) completes Phase 1b enrollment of 21; extension approved - Stock Titan
Sentiment analysis tools applied to Gain Therapeutics Inc.Weekly Market Report & Free High Return Stock Watch Alerts - newser.com
Advanced analytics toolkit walkthrough for Gain Therapeutics Inc.Quarterly Profit Summary & Weekly High Return Forecasts - newser.com
자본화:
|
볼륨(24시간):